Multiple Myeloma Discussions

ASH 2022

M. Merz, F. Schjesvold, B. C. Lipe, K. Weisel, H. Einsele

Bispecific antibodies - consolidating data, clinical...

Magnetismm-3, MajesTEC-2, GO39775

ASH 2022

M. Merz, F. Schjesvold, B. C. Lipe, K. Weisel

Treatment of high-risk NDMM patients and MRD-driven...

GMMG-Concept, UK OPTIMUM/MUKnine Trial, Myeloma XI, RADAR UK-MRA Myeloma XV

ASH 2022

M. Merz, F. Schjesvold, B. C. Lipe, K. Weisel

Asymptomatic myeloma - what do we really want to...

Ascent Trial, GEM-CESAR

ASH 2022

M. Merz, F. Schjesvold, B. C. Lipe, H. Einsele

CAR-T cells - manufacturing, earlier lines & new...

CC-98633-MM-001, Atalanta-1, KarMMa-2 Cohort 2a, CARTITUDE-2 Cohort B, CC‑95266‑MM‑001

CLL and Lymphoma Discussions

ASH 2022

M. Dreyling, A. Niebla, C. Thieblemont, S. Ferrero, T. Eyre

Glofi - RCHOP in 1st line, Axi-Cel in 2nd line, TMTV...

Alycante, ZUMA-7

ASH 2022

M. Dreyling, A. Niebla, C. Thieblemont, S. Ferrero, T. Eyre

When to treat or not? Watch and wait!? Bispecifics or...

ELM-2, FLIPI24

ASH 2022

M. Dreyling, A. Niebla, C. Thieblemont, S. Ferrero, T. Eyre

Zanu with superior PFS, Pirtobrutinib Update in R/R...

ALPINE, BRUIN

ASH 2022

M. Dreyling, A. Niebla, C. Thieblemont, S. Ferrero, T. Eyre

Do we treat all MCL identically? New data on Ibru,...

TRIANGLE, TARMAC

Newly Diagnosed Multiple Myeloma

ASH 2022

C. Ola Landgren, MD

NDMM highlights

ASH 2022

Maximilian Merz, MD

Maintenance with lenalidomide - how long?

Myeloma XI

ASH 2022

Maximilian Merz, MD

Establish MRI diagnostics early

MRD2STOP, GEM2014MAIN, RADAR

ASH 2022

Katja Weisel, MD

Quadruplet for newly diagnosed high-risk patients

GMMG-Concept

ASH 2022

Brea C. Lipe, MD

To transplant or not?

DSMM XIII

Newly Diagnosed Multiple Myeloma - Multilanguage

ASH 2022

C. Ola Landgren, MD

NDMM highlights

ASH 2022

Hermann Einsele, MD

Kortikoid-Einsparung bei unfitten Patienten unter DR

IFM2017-03

ASH 2022

Maximilian Merz, MD

Erhaltung mit Lenalidomid - wie lange?

Myeloma XI

ASH 2022

Maximilian Merz, MD

MRD-Diagnostik früh etablieren

MRD2STOP, GEM2014MAIN, RADAR

ASH 2022

Katja Weisel, MD

Isa-KRd bei HR NDMM: Hohe MRD Negativität

GMMG-Concept

Relapsed/Refractory Multiple Myeloma

ASH 2022

C. Ola Landgren, MD

Bispecific antibodies highlights

ASH 2022

Brea C. Lipe, MD

Still biting, Talquetamab?

MonumenTAL-1

ASH 2022

Katja Weisel, MD

New generation CAR-T cell therapy with fast...

Nex-T CAR-T

ASH 2022

Maximilian Merz, MD

The future of immunotherapy

MajesTEC-2, KarMMa-2 Cohort 2a

ASH 2022

Hermann Einsele, MD

More treatment options with bispecifics emerging!

ASH 2022

Hermann Einsele, MD

CAR-T cells: new targets and early treatment

ASH 2022

Fredrik Schjesvold, MD

New CAR-T technologies

NEX-T CAR-T, Atalanta-1

ASH 2022

Fredrik Schjesvold, MD

GPRC5D-immunotherapy

MonumenTAL-1

ASH 2022

Fredrik Schjesvold, MD

Bispecific antibodies

GO39775

Relapsed/Refractory Multiple Myeloma - Multilanguage

ASH 2022

C. Ola Landgren, MD

Bispecific antibodies highlights

ASH 2022

Katja Weisel, MD

Neue Generation der CAR-T Zelltherapie mit schneller...

Nex-T CAR-T

ASH 2022

Hermann Einsele, MD

Bispezifische Antikörper: Weitere Behandlungsoptionen...

ASH 2022

Hermann Einsele, MD

CAR-T Zellen: Neue erfolgsversprechende Targets und...

ASH 2022

Maximilian Merz, MD

Die Zukunft der Immuntherapie

MajesTEC-2, KarMMa-2 Cohort 2a

ASH 2022

Fredrik Schjesvold, MD

Nye CAR-T-teknologier

NEX-T CAR-T, Atalanta-1

ASH 2022

Fredrik Schjesvold, MD

GPRC5D immunterapi

MonumenTAL-1

ASH 2022

Fredrik Schjesvold, MD

Bispesifikke antistoffer

GO39775

Smoldering Myeloma/MGUS

ASH 2022

Maximilian Merz, MD

Smouldering myeloma - potentially curable?

GEM-CESAR, ASCENT

ASH 2022

Brea C. Lipe, MD

Plasma cells aren't alone!

Smoldering Myeloma/MGUS - Multilanguage

ASH 2022

Maximilian Merz, MD

Smouldering Myelom – potentiell heilbar?

GEM-CESAR, ASCENT

Mantle Cell Lymphoma

ASH 2022

Ana Marín Niebla, MD

Fixed-duration Glofitamab produces high quality and...

ASH 2022

Toby Eyre, MD

Glofitamab demonstrates high efficacy in r/r MCL

ASH 2022

Toby Eyre, MD

Ibrutinib combined with chemotherapy could replace ASCT

Triangle

ASH 2022

Ana Marín Niebla, MD

Early use of anti-CD19 CAR-T (tisacel) plus ibrutinib...

Tarmac

ASH 2022

Ana Marín Niebla, MD

The R2-Acalabrutinib combination in first-line is...

ASH 2022

Ana Marín Niebla, MD

Ibrutinib added in induction and maintenance improves...

Triangle

ASH 2022

Martin Dreyling, MD

Ibrutinib + Ctx replaces autologous stem cell...

Triangle

ASH 2022

Mats Jerkeman, MD

TRIANGLE - addition of Ibrutinib will improve outcome...

Triangle

ASH 2022

Mats Jerkeman, MD

VALERIA response-adapted treatment for R/R MCL patients

VALERIA

ASH 2022

Mats Jerkeman, MD

Glofitamab in R/R mantle cell lymphoma

Mantle Cell Lymphoma - Multilanguage

ASH 2022

Martin Dreyling, MD

Ibrutinib + Ctx ersetzt autologe...

Triangle

ASH 2022

Mats Jerkeman, MD

TRIANGLE- tillägg av ibrutinib förbättrar...

Triangle

ASH 2022

Mats Jerkeman, MD

Glofitamab för recidiverande MCL

ASH 2022

Mats Jerkeman, MD

Valeria- responsstyrd behandling för recidiverande MCL

VALERIA

ASh 2022

Ana Marín Niebla, MD

Glofitamab en esquema fijo de 12 meses produce...

ASH 2022

Ana Marín Niebla, MD

El uso precoz de CAR-T anti-CD19 (tisacel) e ibrutinib...

Tarmac

ASH 2022

Ana Marín Niebla, MD

El triplete R2-Acalabrutinib en primera línea es...

ASH 2022

Ana Marín Niebla, MD

Ibrutinib en inducción y mantenimiento mejora la...

Triangle

Follicular Lymphoma

ASH 2022

Simone Ferrero, MD

Is watch & wait still valualble in follicular lymphoma?

ASH 2022

Simone Ferrero, MD

Odronextamab in relapsed/refractory follicular lymphoma

ELM-2

ASH 2022

Simone Ferrero, MD

A new FLIPI to predict POD24 in follicular lymphoma

FLIPI24

ASH 2022

Toby Eyre, MD

Epcoritamab - bispecific antibody highly effective in...

EPCORE NHL-2 arm 2b

ASH 2022

Martin Dreyling, MD

Bispecific antibody Epcoritamab s.c. + R2 convincing

EPCORE NHL-2 arm 2b

ASH 2022

Martin Dreyling, MD

Tisagenlecleucel at r/r FL: convincing response more...

Elara Trial

ASH 2022

Martin Dreyling, MD

Watch and Wait remains standard of care

Follicular Lymphoma - Multilanguage

ASH 2022

Simone Ferrero, MD

E' ancora valido il watch & wait nel linfoma...

ASH 2022

Simone Ferrero, MD

Epcoritamab-R2 nel linfoma follicolare...

EPCORE NHL-2 arm 2b

ASH 2022

Simone Ferrero, MD

Odronextamab nel linfoma follicolare...

ELM-2

ASH 2022

Simone Ferrero, MD

Un nuovo FLIPI per predire la POD24 nel linfoma...

FLIPI24

ASH 2022

Martin Dreyling, MD

Bispezifischer Antikörper Epcoritamab s.c. + R2...

EPCORE NHL-2 arm 2b

ASH 2022

Martin Dreyling, MD

Tisagenlecleucel beim r/r FL: Überzeugendes Ansprechen...

Elara Trial

ASH 2022

Martin Dreyling, MD

Watch and Wait bleibt Standard

DLBCL

ASH 2022

Mats Jerkeman, MD

Alycante - axi-cel in transplant-ineligible R/R DLBCL...

Alycante

ASH 2022

Catherine Thieblemont, MD

Two highlight studies in DLBCL treatment

Alycante

DLBCL - Multilanguage

ASH 2022

Mats Jerkeman, MD

Alycante - axi-cel till patienter med tidigt recidiv av...

Alycante

ASH 2022

Catherine Thieblemont, MD

Deux études marquantes dans le traitement du DLBCL

Alycante

Waldenström Macroglobulinemia

ASH 2022

Martin Dreyling, MD

Ventricular arrhythmias under combination ibrutinib +...

Waldenström Macroglobulinemia - Multilanguage

ASH 2022

Martin Dreyling, MD

Ventrikuläre Arrhythmien unter Kombi Ibrutinib +...

Chronic/Small Lymphocytic Leukemia

ASH 2022

Toby Eyre, MD

Zanubrutinib demonstrates superiority in r/r CLL/SLL

ALPINE

ASH 2022

Toby Eyre, MD

Pirtobrutinib shows activity in pre-treated r/r...

BRUIN

Varia

ASH 2022

Brea C. Lipe, MD

Is it time to feed our patients?

Neutrodiet